BBP vs IDNA

BBPAVirtus Biotech ETF

IDNABiShares Genomics Immunology and Healthcare ETF

In short

BBP Biotech, minus the coin flips. BBP tracks an index of US-listed biotech companies that already have at least one FDA-approved therapy, so the basket leans commercial-stage instead of clinical-trial hopefuls.

IDNA Most biotech ETFs hand you the US biotech index. IDNA goes narrower and wider at once: about 50 companies from developed and emerging markets, picked around genomics, immunology and bioengineering.

Stated mandate

BBP The fund seeks to track the LifeSci Biotechnology Products Index, which consists of U.S.-listed biotechnology stocks with at least one FDA-approved drug therapy.

IDNA The Fund seeks to track an index of developed- and emerging-market companies positioned to benefit from long-term growth and innovation in genomics, immunology, and bioengineering.

Why people hold it

• BBP The screen does the heavy lifting: index membership requires at least one FDA-approved drug therapy, which filters out pre-approval story stocks.
• 0.34% a year undercuts the biotech cohort median of 0.50% and sits below IBB's 0.44%.
• Running since 2014 and spread across roughly 200 US-listed names, so one approval or rejection does not decide the whole basket.
• One of the stronger builds in its biotech and genomics peer group, with a portfolio that stays close to the index it promises.

• IDNA The mandate is specific: an index of developed- and emerging-market companies tied to genomics, immunology and bioengineering, not a catch-all biotech basket.ishares.com
• 0.47% a year, a shade under the typical fund in its genomics-and-biotech peer group.
• About 50 holdings, so individual genomics and immunology names carry real weight instead of getting diluted inside a broad healthcare index.
• Running since 2019 under the iShares roof, and it stands in the upper half of its biotech and genomics peer group.

Worth knowing

• BBP Thinly traded and modest in size next to the category's household names. Spreads can widen, which makes limit orders the safer habit.
• Income is not the point here. The fund has not been paying distributions, so the return story is price.
• An approved drug filters risk, it does not erase it. This is a single-sector biotech basket, and sector drawdowns hit everything in it.

• IDNA Concentration cuts both ways: about 50 stocks in one theme, so single-company clinical news lands harder here than in a broad healthcare fund.
• Smaller and less actively traded than the category's giants, so limit orders earn their keep. Emerging-market holdings add currency and local-market risk.
• Broad biotech index funds charge less, IBBQ at 0.19% and IBB at 0.44%; the extra basis points here buy the global genomics-and-immunology tilt.

Full BBP profile⁠

Full IDNA profile⁠